Quid Pro Quo (QPQ) Tracker
← Back to Influence Map
Entity DossierOrganization

BIOTECHNOLOGY INNOVATION ORGANIZATION

DC · US

pharmaceuticals

Tracked direct giving

$0

LDA reported lobbying spend

$14,430,000

Connections

14

Outside Spending and Dark Money

Dark money is election spending by organizations that do not disclose their donors: 501(c)(4) social welfare organizations, 501(c)(6) trade associations, and similar non-committee filers (FEC Form 5 and Form 9). Registered super PACs also make independent expenditures. But they itemize their donors with the FEC, so their spending is not dark money. Figures below are never combined with disclosed-donor totals.

IRS 990 Schedule I Grant Chain

Grants between nonprofits reported on IRS Form 990 Schedule I. Grants between organizations are one route for dark money. A nonprofit may receive a grant from one entity and then spend that money on election ads.

IRS 990 Schedule I grants received

$73,700

GrantorAmountTax YearPurpose
ALZHEIMERS DRUG DISCOVERY FOUNDATION$73,7002023ALZHEIMERS RESEARCH

Source: IRS Form 990 Schedule I (Grants and Other Assistance to Organizations) via ProPublica Nonprofit Explorer and IRS 990 XML e-files. Grant amounts represent the most recent filing year available.

IRS 990 data lags a year or more behind filing. Grants shown are for the stated tax year and do not establish current-cycle funding.

Methodology Disclosure

Dark money figures are derived from FEC Form 5 (independent expenditures by non-committee organizations) and Form 9 (electioneering communications). These filings capture spending on ads and election communications but do not reveal the identity of the organization's donors. QPQ totals may differ from benchmarks like the Brennan Center's estimates. QPQ includes all Form 5 filers, while some benchmarks count only a subset of non-disclosing nonprofits. Grant chain data is from IRS Form 990 Schedule I and may not include all years or all grantee organizations.

Lobbying Activity Detail

Disclosed lobbying expenditures from LDA filings where this entity is the client. Dollar amounts represent what was reported to the Senate Office of Public Records.

Top Lobbying Issues

HCRHealth Issues
$29.3M
TRDTrade
$26.8M
MMMMedicare/Medicaid
$26.2M
TAXTaxation/Internal Revenue Code
$26.2M
BUDBudget/Appropriations
$26.1M
MEDMedical/Disease Research
$25.6M
SMBSmall Business
$25.4M
CPTCopyright/Patent/Trademark
$25.3M
HOMHousing
$25.3M
ANIAnimals
$18.6M

Lobbying Firms Retained

In-house lobbyists (filed as its own registrant)$25.3M
AVOQ, LLC$1.1M
AKIN GUMP STRAUSS HAUER & FELD$880K
BGR GOVERNMENT AFFAIRS$840K
TODD STRATEGY GROUP$480K
DLA PIPER LLP (US)$300K
VALCOUR LLC$220K
SL STRATEGIES, LLC$160K
Arentfox Schiff$10K

Bills Referenced in Lobbying Filings

march-inPBMcorn

Lobbying data from Senate LDA filings and the LobbyView dataset (MIT/NSF, CC-BY-4.0). Dollar figures represent disclosed expenditures only and may not capture all influence activity. Issue codes follow the LDA general issue classification.

Connection Graph
0 nodes · 0 edgesHover for labels · Double-click to expand
Loading graph...
Person
Organization
PAC
Gov Body
Legislature
Think Tank
Industry
Outcome

Click a node to see details

Double-click to expand its connections

Relationships

TypeConnected ToDetailsSource
RetainedAKIN GUMP STRAUSS HAUER & FELDHired AKIN GUMP STRAUSS HAUER & FELD to lobby on PharmaceuticalsSource
Lobbied onPharmacy Benefit Manager Reform ActLDA filing: lobbied on PBM Reform Act, period 1st Quarter (Jan 1 - Mar 31), reported amount $60,000Source
Lobbied onMARCH-IN Rights Proposal (NIH Framework)LDA filing: lobbied on NIH March-In Rights, period 1st Quarter (Jan 1 - Mar 31), reported amount $2,430,000Source
Lobbied on2023 Farm Bill Reauthorization (Corn Provisions)LDA filing: lobbied on Farm Bill Corn Provisions, period 1st Quarter (Jan 1 - Mar 31), reported amount $2,430,000Source
Commented onFederal Trade CommissionPublic comment on FTC-2023-0040: Premerger Notification; Reporting and Waiting Period RequirementsSource
Commented onCenters for Medicare & Medicaid ServicesPublic comment on CMS-2025-1889: Global Benchmark for Efficient Drug Pricing ModelSource
RetainedTODD STRATEGY GROUPHired TODD STRATEGY GROUP to lobby (1st Quarter (Jan 1 - Mar 31) 2023)Source
RetainedAVOQ, LLCHired AVOQ, LLC to lobby (1st Quarter (Jan 1 - Mar 31) 2023)Source
RetainedVALCOUR LLCHired VALCOUR LLC to lobby (2nd Quarter (Apr 1 - June 30) 2025)Source
RetainedSL STRATEGIES, LLCHired SL STRATEGIES, LLC to lobby (1st Quarter (Jan 1 - Mar 31) 2023)Source
RetainedArentfox SchiffHired ARENTFOX SCHIFF LLP to lobby (1st Quarter (Jan 1 - Mar 31) 2023)Source
RetainedBGR GOVERNMENT AFFAIRSHired BGR GOVERNMENT AFFAIRS to lobby (1st Quarter (Jan 1 - Mar 31) 2023)Source
RetainedDLA PIPER LLP (US)Hired DLA PIPER LLP (US) to lobby (2nd Quarter (Apr 1 - June 30) 2025)Source
Received money fromALZHEIMERS DRUG DISCOVERY FOUNDATIONIRS 990 Schedule I grant of $73,700 (tax year 2023). Purpose: ALZHEIMERS RESEARCHSource